

FACULTY OF HEALTH AND MEDICAL SCIENCES

UNIVERSITY OF COPENHAGEN



Design of spray-dried TNF- α siRNA-loaded LPNs with high aerosol performance for treatment of COPD


You Xu^{1*}, Aneesh Thakur¹, and Camilla Foged¹, *you.xu@sund.ku.dk ¹ Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark


Introduction:

Therapeutics based on siRNA are highly target-specific and promising for the treatment of chronic obstructive pulmonary disease (COPD)^{1,2}. Local delivery of siRNA to the lungs constitutes a promising new area in drug delivery. The aim of the present study was to design inhalable formulations of siRNA-loaded lipidoid-polymer hybrid nanoparticles (LPNs) by spray drying (SD) using the sugars trehalose and dextran as stabilizing excipients and the amino acid leucine as dispersion enhancer.

Hypothesis:

The aerosolization properties of the powder-based solid dosage forms of TNF-α siRNA-loaded LPNs can be improved by using a combination of amino acid and sugars during the spray drying process.









Fig. 5. Scanning electron microscope images of spray-dried LPNs. The scale bare represent 10 µm.



L/T/D 50:50(10:90)

L/T/D 60:40(10:90)

Fig. 6. Thermal gravimetric analysis of the spray-dried LPNs





Fig. 7. X-ray powder diffraction profiles of spray-dried LPNs

Fig. 3. The yield (A), moisture content (B), and mass median aerodynamic diameter



Conclusions

1. Inclusion of the dispersion enhancer leucine into the trehalose:dextran sugar mixture of spray dried excipients enhances the aerosol performance of the resulting powders in PreciseInhale system. 2. The leucine content should be kept below 60% because leucine influences the particle size and distribution after spray drying, as well as the surface morphology.

3. The highest aerosol performance was achieved for the formulation containing 40% leucine and 60% Trehalose/Dextran (10:90), hence it is promising for *in vivo* lung powder deposition studies.

References:

1. Thanki, Kaushik, et al. Eur. J. Pharm. Biopharm. 120 (2017), 22-33. 2. Jansen, Manon AA, et al. Eur J Pharm Biopharm. 142 (2019), 38-48. 3. Thanki, Kaushik, et al. Springer New York. (2019), 141-52. 4. Dormenval, Cypriane, et al. Pharm. Res. 36.10 (2019): 142.

Acknowledgements: We gratefully acknowledge the financial support from the Novo Nordisk Foundation, Denmark (grant no. NNF17OC0026526) and Independent Research Fund, Denmark (grant no. DFF-4184-00422). We acknowledge the China Scholarship Council (CSC) for the Scholarship to You Xu (201906210064).